Anti-LILRA6 CAR-T cells therapy (Second Affiliated Hospital School Of Zhejiang University School Of Medicine)

N/A

Report date: 2025/12/05 20:00:50

Base Information

Drug NameAnti-LILRA6 CAR-T cells therapy (Second Affiliated Hospital School Of Zhejiang University School Of Medicine)
Drug Alias NameN/A
ClassificationCell and gene therapy > Cell therapy > Immune system cell therapy > Lymphocytes therapy > T-lymphocyte cell therapy > Chimeric antigen receptor T cell therapyCell and gene therapy > Gene therapy > Viral vector-based gene therapy > Lentiviral vector
Mechanisms of ActionAnti-Leukocyte immunoglobulin-like receptor subfamily B member 3T lymphocyte replacements
TargetsLeukocyte immunoglobulin-like receptor subfamily B member 3
Therapy Area/IndicationsLeukemia, Myeloid, Acute
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryMainland China
CombinationsNo
Global Highest StatusPhase 1 Clinical
Highest Status in ChinaPhase 1 Clinical
Originator CompaniesSecond Affiliated Hospital School Of Zhejiang University School Of Medicine
China Registration ClassN/A

Develop Information

Active CompaniesSecond Affiliated Hospital School Of Zhejiang University School Of Medicine
Inactive CompaniesN/A
Active IndicationsLeukemia, Myeloid, Acute
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A